Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Liam on +44 1494 818 027 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Liam Whelan
Senior Account Manager
+44 1494 818 027

I would like to complement and pass on my grateful thanks to Zenopa for the excellent service they have provided myself with since I have been on your books since October 2011.
Doug, 2013

Roche ends collaboration with Ligand

26 November 2010 00:00 in Pharmaceutical Company Product News

Roche has ended its agreement with Ligand Pharma after two years.

The two firms signed a collaboration and license agreement to develop new treatments for hepatitis C viral infections in 2008, but Roche is exercising its right to terminate the agreement.

Roche made a $6.5 million (4.1 million pounds) milestone payment to Ligand in April this year, following the initiation of the RG7348 Phase I clinical trial.

Under the terms of the agreement, Ligand will now receive a non-exclusive, worldwide, royalty-bearing license under specified Roche patents to develop and sell related compounds and products.

Roche will be unable to develop or commercialise related compounds for the next ten years.

Ligand received notice of the termination on Friday November 19th 2010. It is expected that the termination will be in effect 60 days after written notice was given.

Earlier this month, it was reported that Roche has embarked on a strategic partnership with Capital Bio, targeting molecular diagnostic applications and the development of research technologies.ADNFCR-8000103-ID-800257273-ADNFCR

Other news stories from 26/11/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd